Filing Flows

Filing Flows › Companies › Serina Therapeutics › Cash flow

Serina Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.7M in Q2 2026 · −$21.2M over twelve months

Operating cash flow−$6.7M
Capital spending−$28K
Free cash flow−$6.7M

Analysis

In Q2 2026, Serina Therapeutics generated −$6.7M of operating cash flow and spent $28K on capital projects, leaving free cash flow of −$6.7M. That is $2.9M less than in Q2 2025 (−$3.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$21.1M; the largest uses were operating cash flow ($21.1M), capital spending ($66K); besides operations, cash came from other financing ($38.2M), shares issued ($22K); the cash balance rose by $17.0M.

Operating cash flow was −$6.7M against net income of −$6.4M. The largest differences: stock-based pay +$1.1M, payables −$967K, prepaid and other assets −$164K.

Free cash flow

Serina Therapeutics: free cash flow by quarterSerina Therapeutics: free cash flow by quarter−$3.0MQ3 2024−$4.6MQ4 2024−$4.3MQ1 2025−$3.8MQ2 2025−$3.9MQ3 2025−$6.0MQ4 2025−$4.6MQ1 2026−$6.7MQ2 2026
Operating cash flow less capital spending.
Serina Therapeutics: operating cash flow against capital spendingSerina Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$3.0M$3KQ3 2024−$4.6M$5KQ4 2024−$4.3M$0Q1 2025−$3.8M$46KQ2 2025−$3.9M$13KQ3 2025−$6.0M$0Q4 2025−$4.6M$25KQ1 2026−$6.7M$28KQ2 2026
Latest (Q2 2026): Operating cash flow −$6.7M, Capital spending $28K.

Capital allocation, year by year

Serina Therapeutics: where the cash came from (up) and went (down), by fiscal yearSerina Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$7.9MFY2021: Net borrowing $7.0MFY2021: Shares issued $8.3M$15.3MFY2021FY2022: Operating cash flow −$5.9MFY2022: Net borrowing $6.0MFY2022: Shares issued $7.3M$13.3MFY2022FY2023: Operating cash flow −$2.5MFY2023: Net borrowing $10.0MFY2023: Shares issued $15KFY2023: Capital spending −$504K$10.0MFY2023FY2024: Operating cash flow −$17.1MFY2024: Net borrowing $3.0MFY2024: Shares issued $12KFY2024: Capital spending −$22K$3.0MFY2024FY2025: Operating cash flow −$18.0MFY2025: Net borrowing $4.9MFY2025: Shares issued $5.0MFY2025: Capital spending −$59K$9.9MFY2025
Over these 5 years operating cash flow totalled −$51.4M; the largest uses were operating cash flow ($51.4M) and capital spending ($585K). Cash-flow statements as filed.

Where the cash came from and went

Serina Therapeutics: sources (+) and uses (−) of cash, Q2 2026Serina Therapeutics: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$6.7MOther financing$5.2MCash drawn (+) / kept (−)$1.5MCapital spending−$28KExchange rates$8KShares issued$1K
Serina Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Serina Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$38.2MOperating cash flow−$21.1MCash drawn (+) / kept (−)−$17.0MCapital spending−$66KShares issued$22K

From profit to cash

Serina Therapeutics: net income to operating cash flow, Q2 2026Serina Therapeutics: net income to operating cash flow, Q2 2026Net income−$6.4MDepreciation & amortization$18KStock-based pay$1.1MPayables−$967KAccrued liabilities−$49KPrepaid and other assets−$164KOther liabilities−$23KOperating cash flow−$6.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$6.7M−$28K—$1K$1.5M−$6.7M
Q1 2026−$4.6M−$25K—$8K−$21.5M−$4.6M
Q4 2025−$6.0M——$5K$5.6M−$6.0M
Q3 2025−$3.9M−$13K—$8K−$2.6M−$3.9M
Q2 2025−$3.8M−$46K—$1K−$1.8M−$3.8M
Q1 2025−$4.3M——$4.9M−$595K−$4.3M
Q4 2024−$4.6M−$5K$108K−$78K−$437K−$4.6M
Q3 2024−$3.0M−$3K−$8K$86K$2.9M−$3.0M

Serina Therapeutics: income statement and cash flow

Serina Therapeutics, Q2 2025: revenue $130K (+155% year over year). The chart follows the revenue to costs, profit and cash.

Serina Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.